2008-07-02 20:11:18 -
www.companiesandmarkets.com adds new report - Premium Company Profile - Endo Pharmaceuticals www.companiesandmarkets.com/Summary-Company-Profile/Premium-Comp ..
Introduction
Endo Pharmaceuticals´ main focus is to develop and market prescription drugs for pain management. The company´s marketed product, Lidoderm, indicated for the relief of pain associated with post-herpetic neuralgia, has been the major contributor to its revenues. Further, the company´s acquisition of RxKinetix in 2006 provided an expansion of the company into therapeutic areas.
Scope
Contains corporate strategy,
value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals. The company has a portfolio of branded products that includes: Lidoderm, Percocet, Frova, Percodan, Opana, Opana ER and Synera.
The company´s lead product candidate EN 3285 Oral Rinse for treating Oral mucositis is currently in Phase 2 clinical trials. In addition, Endo Pharmaceuticals has two licensed products in Phase 3 namely: topical ketoprofen patch and rapinyl used for treating pain associated with soft tissue injuries and cancer, respectively.
Endo Pharmaceuticals derives its revenues from product sales of its proprietary and in-licensed products. The company´s total revenues increased at a CAGR of 10.9% during 2002-2006, from $399 million to $909.7 million. This represents an absolute total growth of +$510 million for total revenues.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
